Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) with a clinical picture dominated by erythrocytosis, some extent of thrombocytosis and leukocytosis, and a high risk of thrombosis with a late potential evolution toward myelofibrosis (post-PV MF) and acute myeloid leukemia (AML). 1 The as yet unfinished story of PV pathogenesis started with the discovery of the JAK2 (V617F) mutation;
2 afterwards other mutations were found in PV, such as the exon 12 mutations of JAK2, 3, 4 or mutations of the LNK 5 and TET2 6 genes. 7 The former three involve JAK--STAT signaling activation, whereas TET2 mutations involve chromatin remodeling. 8 Erythrocytosis uncovers heterogeneous conditions ranging from benign to clonal diseases, 9 and clinicians should apply a logical flowchart just to avoid looking for JAK2 mutations in every case of erythrocytosis. To some extent, the management of PV patients appears to be simple. However, much of the so-called standard therapy has been established with a lack of data, and so considerable uncertainty still remains. 10 The suggested management described herein reflects an approach through clinical vignettes describing patients commonly encountered in daily practice.
PATIENT NO. 1 A 43-year-old athlete woman was referred with isolated erythrocytosis, without thrombocytosis or leukocytosis. Her hemoglobin level was 21 g/dl and hematocrit 59.2%; there was no enlargement of the spleen at the visit. She had no PV-related symptoms (microvascular disturbances, pruritus and headache), but complained regarding arterial hypertension. The questions from this case are as follows: What are the claims for the interview? What examinations need to be done? What is the diagnosis?
In the case of isolated erythrocyotosis, I first excluded secondary polycythemia. This young female neither smokes nor refers about pulmonary or cardiac problems. Her oxygen saturation was 98% and abdomen scan revealed no abnormality. I assigned a critical role to serum erythropoietin level: if it is high the diagnosis of secondary erythrocytosis is likely. I asked her about family history of erythrocytosis or MPN. I suggested placing attention on familial history, especially in the case of isolated erythrocytosis. Primary familial and congenital polycythemia (PFCP) is an autosomal dominant disease with mutational lesions (found in 10 --15% of the cases) truncating erythropoietin receptor (EpoR) expression, with subsequent loss in the negative regulator domain leading to a final activation of the JAK2 --STAT pathway. Patients with PFCP may present with isolated erythrocytosis and low levels of serum erythropoietin (Epo), no spleen enlargement and a predisposition to severe cardiovascular problems. Congenital polycythemia due to altered hypoxia sensing belongs to another group of hereditary erythrocytosis. The oxygen-sensing pathway consists of different proteins involved in the regulation of erythropoietin production: hypoxia inducible factor (HIF), von Hippel Lindau protein (VHL) and prolyl hydroxylase proteins (PDH). 11 Normoxia induces PDH hydroxylation, improving VHL binding to HIF1a and resulting in the proteasome-mediated degradation of HIF1a. In hypoxic condition, the hydroxylation is inhibited; hence the increased levels of HIF1a activate transcription of the Epo gene, leading to isolated erythrocytosis. 12 After the first defect of the oxygensensing pathway involving VHL gene was described in the Chuvash population of Russia, 13 different patterns of mutations involving VHL, PDH and HIF genes have been described so far. 14 The disease is generally characterized by erythrocytosis, normal --high levels of epo, headache, frequent thrombosis, and an autosomal recessive or dominant inheritance. Other causes of inherited erythrocytosis with high serum epo include cyanotic congenital heart disease, inherited conditions that increase the affinity of hemoglobin for oxygen, including high-affinity hemoglobin disorders, deficiency of 2,3 BPG (I recommend screening for P 50 level) and methemoglobinemia. In my clinical practice, to discriminate familial erythrocytosis, I interview the patient elaborately and then guide mutational analyses on the basis of serum epo level. As these tests are not usually available outside the research setting, I suggest contacting National Referral Centers for blood sampling instruction and delivery to have uniform results. Also, familial PV may occur with a frequency of roughly 6 --7%. 15 The patient was not aware of familial erythrocytosis in her relatives and so I did not investigate specific molecular tests.
Hence, I tested serum erythropoietin level, which was below the normal limit: 1 mU/ml. In the case of erythrocytosis with a low level of erythropoietin, diagnosis of PV is likely and I studied JAK2 mutations. I currently assess the JAK2 (V617F) mutation first, and JAK2 exon 12 mutations if V617 is negative. In the very few cases without any JAK2 mutation, but with low erythropoietin, I suggest investigating LNK mutations. I generally quantify the JAK2 (V617F) mutation on isolated neutrophils, 16 but if it is not with a research intent, a qualitative test on whole leukocytes is the correct approach. 17 The final diagnosis was PV according to the WHO classification, 9 as the patient presented with a hemoglobin level 416.5 g/dl and harbored the JAK2 (V617F) mutation. Regarding bone marrow biopsy, I check the bone marrow of my patients with PV at diagnosis to capture potentially useful information, but I explain to them that no data are available on the diagnostic/ prognostic value of this invasive procedure in PV and leave them free to decide. Pathologists should give information at least on marrow cellularity and bone marrow fibrosis, according to well-defined criteria. 18 In PV, the marrow is usually hypercellular for age with trilineage growth and prominent erythroid, granulocytic and megakaryocytic proliferation, and bone marrow fibrosis is generally absent, 9 but in B20% of cases grade 1 fibrosis may be found. I always check bone marrow biopsy in highly suspected PV cases without JAK2 mutations. When I perform bone marrow biopsy, I include evaluation of cytogenetics, although very few patients with PV have an abnormal karyotype, and this seems to be not of prognostic value. 19 In conclusion, my diagnostic approach in case of isolated erythrocytosis is based on the visit and interview of patients, and on checking the causes of secondary erythrocytosis. If the causes of secondary erythrocytosis are not evident and serum erythropoietin level is low --normal, I study JAK2 mutations. If serum erythropoietin level is high, I do not investigate JAK2 mutations, but deeply explore the causes of secondary erythrocytosis by chest X-ray, echocardiography, high-resolution CT scan, lung function test, polysonography and P 50 levels. In the case of a patient with erythrocytosis and other signs of myeloproliferation, such as leukocytosis, thrombocytosis or splenomegaly, the diagnosis of PV is likely and I test serum erythropoietin and JAK2 mutations first.
PATIENT NO. 2 A 58-year-old man was referred with diagnosis of PV, made two years before, during an admission in hospital for myocardial infarction. The patient was regularly receiving phlebotomy to control erythrocytosis. His hematocrit was 43%, WBC 15 Â 10 9 /l, platelet count 758 Â 10 9 /l and he had mild splenomegaly (4 cm below the costal margin). At the time of diagnosis, the patient did not have leukocytosis or splenomegaly but only a mild thrombocytosis, without history of thrombosis. The questions from this case are as follows: What was his prognostic risk? Was the treatment appropriate for this patient at diagnosis? What treatment should the patient be administered now? How should he be followed up?
At diagnosis, the patient had PV according to the WHO criteria, as he had a hemoglobin level 418.5 g/dl (21 g/dl) and the JAK2 (V617F) mutation. Regarding the patient's risk stratification at diagnosis, he had PV at a high risk of thrombosis, as he suffered from myocardial infarction. In fact, the current risk stratification of PV, as recommended by European Leukemia Net, is based on two main risk factors for thrombosis: age 460 years and history of thrombosis. 10, 20 If a patient has one of these two risk factors, he/she should be considered to be at high risk and should receive cytotoxic therapy. 10 Hence, in this case, the patient was to be treated from diagnosis with cytotoxic agents.
In my practice, I focus the patient communication on the risks of the disease, the life expectancy and the problem of a long-term therapy.
The ECLAP trial on 1638 patients with PV showed that the incidence of thrombosis is 2.5 Â 100 persons per year for patients o65 years without prior thrombosis, and it becomes twofold higher in those who present at an older age or with prior thrombosis reaching a fourfold higher incidence in the presence of both factors. 21 In my evaluation, I take into account other risk factors too, although these may not guide my therapeutic decision. As almost all patients with PV carry one JAK2 mutation (V617F or other within exon 12), the presence of the mutation per se is not a candidate parameter for risk stratification. I deem that the quantification of the JAK2 (V617F) allele burden might give interesting information in PV, although quantification is not yet standardized. 22 We studied prospectively 320 PV patients according to mutational load (o50% alleles versus X50% alleles) and did not find a relationship between allele burden and thrombosis. 23 A prior retrospective analysis showed that patients with a very high allele burden (X75% alleles) have a higher risk of developing thrombosis when compared with those with a lower quartile (1 --25%). 24 Leukocytosis is another parameter extensively investigated in PV, where some degree of relationship with thrombosis has been found. 25, 26 A leukocyte count 415 Â 10 9 /l was associated with myocardial infarction in the ECLAP trial, 27 and with counts 49.5 Â 10 9 /l with thrombosis in 187 PV and ET cases; 28 conversely, no correlation has been found in 407 low-risk ET and PV patients from the Mayo Clinic. 29 Regarding the incidence of late events as AML 30, 31 and post-PV MF, I mention to patients the following figures: a 15-year cumulative risk of 7% and 6% for AML and post-PV MF, respectively. 32 These events are very difficult to predict, but I discuss the association of post-PV MF with leukocytosis 415 Â 10 9 /l 1 and with higher JAK2 (V617F) allele burden, but I advise patients that this information needs to be confirmed by other trials. Information on the clinical relevance of bone marrow histopathology is elusive in PV, and cytogenetic profile does not affect survival. 19 So, in conclusion, I use age and prior thrombosis to stratify patients with PV, but I register leukocyte count and the JAK2 allele burden, following patients with a high leukocyte count or high allele burden more carefully.
The life expectancy of a PV patient is lesser compared with that of the general population, even if the survival of these patients approaches 20 years. 32 I start treatment with phlebotomy to reduce hematocrit to o45%. In general, I do not prescribe blood removal exceeding 400 cm 3 per procedure, and in patients aged 470 years or younger with severe cardiovascular disease I never exceed 300 cm 3 of blood removal. I continue phlebotomy at a frequency of twice a week or lesser to maintain an adequate control of hematocrit. On the basis of the results obtained in the ECLAP trial, I use aspirin in all PV patients, if not contraindicated, and withdraw aspirin in the case of bleeding or gastric intolerance. In the case of high-risk patients (aged 460 years or with prior thrombosis), as in this patient, or in the case of low-risk patients who develop over time leukocytosis (leukocyte count 420 Â 10 9 /l), thrombocytosis (platelet count 41500 Â 10 9 /l) or splenomegaly 45 --10 cm from the costal margin, I add cytotoxic therapy. Treating patients with PV and leukocytosis might have the potential role to control the disease evolution to post-PV MF, 1 AML 33, 34 and the risk of thrombosis. 27 An intriguing point is whether we should treat patients aged 61 years only on the basis of their being aged 460 years. I think that we should deal with the issue case by case, discussing with patients the benefit/risk profile of the options 'treat' or 'wait'. We have no dynamic model to predict whether the passing from 59 to 61 years is a risk factor per se, but we know for sure that age is a risk factor for thrombosis in all PV studies and for AML in the vast majority. As I consider that the burden of knowledge is in favor of treating patients aged 460 years with cytotoxic agents, I do it if patients agree. Concerning cytotoxic therapy in PV, hydroxyurea (HU) was demonstrated to be very effective in preventing thrombosis in PV and essential thrombocythemia, 35 --38 and thus should be considered the drug of choice in high-risk patients. 10 I administer HU at a dose ranging from 1000 to 1500 mg daily, according to the extent of myeloproliferation (high dose in the case of leukocytosis, thrombocytosis and splenomegaly), the symptomatic burden and the urgency (critical situation, surgery). I recommend my patients consuming HU to avoid pregnancy. 39 --41 Alternatively, in young female patients I use interferon-a, and I am very interested in the potential of reducing the JAK2 (V617F) allele burden in PV, as recently demonstrated. 42, 43 In older patients, I take into consideration pipobroman as first-or second-line therapy. 35, 44, 45 The recent data from Sweden are very reassuring on the potential risk of evolution using HU, and draw our attention to the natural 25% risk of evolution into AML of patients with myeloproliferative neoplasms who are left untreated. 46 In my practice, I never use P 32 or busulfan in PV patients. However, these drugs are considered to be the treatment options for older patients by many hematologists.
In conclusion, I stratify patients at diagnosis of PV according to age and history of thrombosis. I start HU for patients at high risk of thrombosis, while I continue phlebotomy in other cases. All patients, if not contraindicated, receive aspirin. I follow patients monthly until normalization of their blood cell counts or splenomegaly, and afterwards every 2 months with visit, cell blood count and blood smear evaluation. I perform bone marrow biopsy only in the case of clinical signs of disease evolution.
PATIENT NO. 3
A 63-year-old man was referred with a 22-year PV without history of thrombosis and with progressive splenomegaly (24 cm from the costal margin), anemia (hemoglobin 9.8 g/l), mild thrombocytopenia (platelet count 105 Â 10 9 /l) and leukocytosis (WBC 32 Â 10 9 /l). The last phlebotomy was conducted 3 years previously and he started taking HU 5 years before for spleen enlargement and leukocytosis. The questions from this case are the following: What is the diagnosis? What is the prognostic risk? What is the treatment?
In this condition, a diagnosis of disease evolution is likely. So I checked his blood smear, finding leukoerythroblastosis and dacryocytes, and performed bone marrow biopsy, which showed a high degree of myelofibrosis: grade 3. 18 The final diagnosis was post-PV MF, 47 as the patient fulfilled the International Working Group on Myeloproliferative Research and Treatment (IWG-MRT) criteria. 48 These criteria require previous diagnosis of PV (WHO criteria) and bone marrow fibrosis grade 2 --3 (on a 0 --3 scale), and any of two factors among anemia or sustained loss of requirement of phlebotomy or cytoreduction, leukoerythroblastic peripheral blood picture, increasing splenomegaly and development of one or more of three constitutional symptoms (X10% weight loss in 6 months, night sweats and unexplained fever 437.5 1C).
Regarding prognostication, there is a single specific model (dynamic) to predict survival in post-PV MF. 1 This model is based on three risk factors: hemoglobin level o10 g/dl, leukocyte count 430 Â 10 9 /l and platelet count o100 Â 10 9 /l. The low-risk group includes patients without risk factors: hemoglobin X10 g/dl, platelet count X100 Â 10 9 /l and white blood cell count po30 Â 10 9 /l. Conversely, higher-risk categories include patients with one, two or three risk factors. When a patient acquires one risk factor at any time from the diagnosis of post-PV MF, his or her survival worsens by 4.2-fold. Although this is not completely correct, many investigators predict survival in post-PV MF by applying prognostic models developed in primary myelofibrosis, such as the IPSS (International Prognostic Scoring System) developed at diagnosis 49 or the DIPSS (Dynamic International Prognostic Scoring System) developed in a time-dependent manner, 50, 51 or its last evolution (DIPSS-plus), including DIPSS categories, cytogenetics, red blood cell transfusion need and platelet count. 52 In the IPSS and the DIPSS, predictors of shortened survival are age 465 years, presence of constitutional symptoms, hemoglobin level o10 g/dl, leukocyte count 425 Â 10 Treatment of patients with post-PV MF is mainly focused on symptoms, on splenomegaly and on anemia, as in primary myelofibrosis. 10 The first step of my judgment is to decide whether the single patient might benefit from allogeneic stem cell transplantation (allo-SCT) balancing the eradicative potential (median 5 year survival B50%), with its expected risk of death (B20 --45%) or its chronic morbidity from graft-versus-host disease. 53 --57 For the time being, I indicate allo-SCT to post-PV MF patients o65 years with a higher risk of IPSS/DIPSS disease (intermediate-2 and high risk: o4 years as median survival), worse cytogenetics and with a good profile of the comorbidity score. 58 Therefore, given my indication for allo-SCT, I favor the use of conventional-intensity conditioning transplantation in younger patients (age o50 years) for a lower risk of relapse, and I offer reduced-intensity conditioning transplantation for older patients. Unfortunately, the median advanced age of these patients and the worse profile of comorbidity often due to the very long course of PV make the hypothesis of allo-SCT very unreliable in post-PV MF. If allo-SCT is not an option and the patient is not a candidate for investigative treatment, I continue HU for symptoms, splenomegaly, leukocytosis and add prednisone (1 mg/kg daily for 2 --3 months), or danazol (200 --400 mg daily) for treating anemia. Among off-label therapies, I use low-dose thalidomide plus prednisone (Mayo protocol) 59 to improve anemia in some instances, although responses are not satisfactorily around 20%, 59, 60 and I may confirm that not many patients continue thalidomide for a long time because of peripheral neuropathy. In the case of anemia and renal impairment I use erythropoietin, 61 frequently monitoring the spleen size.
Although the discussion on investigative therapies is outside the interest of this position paper as they represent a possibility outside clinical practice, I wish to mention pomalidomide as an emerging treatment for anemia, 62 and ruxolitinib (50 post-PV MF cases treated in phase II study) 63 and TG101348 (12 post-PV MF cases treated in phase II study), belonging to the JAK2 inhibitor category, as safe and active therapies for the treatment of symptoms and splenomegaly with a net benefit for patients. 63, 64 In conclusion, post-PV MF now has strict criteria for diagnosis that should be applied. Treatment is mainly palliative as allo-SCT is offered to few younger patients. A great challenge in the future years is that coming from new investigative therapies. By waiting for the perfect drug, such as imatinib for chronic myeloid leukemia, we have in clinical trials different opportunities to improve the quality of life of these patients.
